Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pilepich, M. V.
Right arrow Articles by Grignon, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pilepich, M. V.
Right arrow Articles by Grignon, D.

Journal of Clinical Oncology, Vol 15, 1013-1021, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase III trial of androgen suppression using goserelin in unfavorable- prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

MV Pilepich, R Caplan, RW Byhardt, CA Lawton, MJ Gallagher, JB Mesic, GE Hanks, CT Coughlin, A Porter, WU Shipley and D Grignon
Catherine McAuley Health Systems, Ann Arbor, MI, USA.

PURPOSE: Although androgen suppression results in a tumor response/remission in the majority of patients with carcinoma of the prostate, its potential value as an adjuvant has not been substantiated. MATERIALS AND METHODS: In 1987, the Radiation Therapy Oncology Group (RTOG) initiated a randomized phase III trial of adjuvant goserelin in definitively irradiated patients with carcinoma of the prostate. A total of 977 patients had been accessioned to the study. Of these, 945 remained analyzable: 477 on the adjuvant arm and 468 on the observation arm. RESULTS: Actuarial projections show that at 5 years, 84% of patients on the adjuvant goserelin arm and 71% on the observation arm remain without evidence of local recurrence (P < .0001). The corresponding figures for freedom from distant metastases and disease-free survival are 83% versus 70% (P < .001) and 60% and 44% (P < .0001). If prostate-specific antigen (PSA) level greater than 1.5 ng is included as a failure (after > or = 1 year), the 5-year disease- free survival rate on the adjuvant goserelin arm is 53% versus 20% on the observation arm (P < .0001). The 5-year survival rate (for the entire population) is 75% on the adjuvant arm versus 71% on the observation arm (P = .52). However, in patients with centrally reviewed tumors with a Gleason score of 8 to 10, the difference in actuarial 5- year survival (66% on the adjuvant goserelin arm v 55% on the observation arm) reaches statistical significance (P = .03). CONCLUSION: Application of androgen suppression as an adjuvant to definitive radiotherapy has been associated with a highly significant improvement in local control and freedom from disease progression. At this point, with a median follow-up time of 4.5 years, a significant improvement in survival has been observed only in patients with centrally reviewed tumors with a Gleason score of 8 to 10.


This article has been cited by other articles:


Home page
 JCOHome page
J. A. Efstathiou, K. Bae, W. U. Shipley, G. E. Hanks, M. V. Pilepich, H. M. Sandler, and M. R. Smith
Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31
J. Clin. Oncol., January 1, 2009; 27(1): 92 - 99.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Roach III, K. Bae, J. Speight, H. B. Wolkov, P. Rubin, R. J. Lee, C. Lawton, R. Valicenti, D. Grignon, and M. V. Pilepich
Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610
J. Clin. Oncol., February 1, 2008; 26(4): 585 - 591.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. B. Shahinian, Y.-f. Kuo, J. L. Freeman, E. Orihuela, and J. S. Goodwin
Characteristics of Urologists Predict the Use of Androgen Deprivation Therapy for Prostate Cancer
J. Clin. Oncol., December 1, 2007; 25(34): 5359 - 5365.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. L. Keating, A. J. O'Malley, and M. R. Smith
Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer
J. Clin. Oncol., September 20, 2006; 24(27): 4448 - 4456.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. B. Shahinian, Y.-F. Kuo, J. L. Freeman, and J. S. Goodwin
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
J Natl Cancer Inst, June 21, 2006; 98(12): 839 - 845.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. E. Studer, P. Whelan, W. Albrecht, J. Casselman, T. de Reijke, D. Hauri, W. Loidl, S. Isorna, S. K. Sundaram, M. Debois, et al.
Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891
J. Clin. Oncol., April 20, 2006; 24(12): 1868 - 1876.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Ogawa, K. Nakamura, H. Onishi, T. Sasaki, M. Koizumi, Y. Shioyama, T. Komiyama, Y. Miyabe, T. Teshima, and Japanese Patterns of Care Study Working Subgroup o
Radical External Beam Radiotherapy for Prostate Cancer in Japan: Results of the 1999-2001 Patterns of Care Process Survey
Jpn. J. Clin. Oncol., January 1, 2006; 36(1): 40 - 45.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Cooperberg, J. W. Moul, and P. R. Carroll
The Changing Face of Prostate Cancer
J. Clin. Oncol., November 10, 2005; 23(32): 8146 - 8151.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. L. Speight and M. Roach III
Radiotherapy in the Management of Clinically Localized Prostate Cancer: Evolving Standards, Consensus, Controversies and New Directions
J. Clin. Oncol., November 10, 2005; 23(32): 8176 - 8185.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Gleave and W. K. Kelly
High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy
J. Clin. Oncol., November 10, 2005; 23(32): 8186 - 8191.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Ryan and E. J. Small
Early Versus Delayed Androgen Deprivation for Prostate Cancer: New Fuel for an Old Debate
J. Clin. Oncol., November 10, 2005; 23(32): 8225 - 8231.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
F Labrie, V Luu-The, A Belanger, S-X Lin, J Simard, G Pelletier, and C Labrie
Is dehydroepiandrosterone a hormone?
J. Endocrinol., November 1, 2005; 187(2): 169 - 196.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
N. Sharifi, J. L. Gulley, and W. L. Dahut
Androgen Deprivation Therapy for Prostate Cancer
JAMA, July 13, 2005; 294(2): 238 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
F. Labrie, A. Belanger, V. Luu-The, C. Labrie, J. Simard, L. Cusan, J. Gomez, and B. Candas
Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer
Endocr. Rev., May 1, 2005; 26(3): 361 - 379.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
F.C.H. d'Ancona and F.M.J. Debruyne
Endocrine approaches in the therapy of prostate carcinoma
Hum. Reprod. Update, May 1, 2005; 11(3): 309 - 317.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. R. Cooperberg, D. P. Lubeck, M. V. Meng, S. S. Mehta, and P. R. Carroll
The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management
J. Clin. Oncol., June 1, 2004; 22(11): 2141 - 2149.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Roach III
In Reply:
J. Clin. Oncol., June 1, 2004; 22(11): 2255 - 2257.
[Full Text] [PDF]

Home page
 J AndrolHome page
F. Labrie
Medical Castration With LHRH Agonists: 25 Years Later With Major Benefits Achieved on Survival in Prostate Cancer
J Androl, May 1, 2004; 25(3): 305 - 313.
[Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Ogawa, K. Nakamura, T. Sasaki, T. Yamamoto, M. Koizumi, T. Inoue, T. Teshima, and the Japanese Patterns of Care Study Working Subgro
Radical External Beam Radiotherapy for Prostate Cancer in Japan: Preliminary Results of the Changing Trends in the Patterns of Care Process Survey between 1996-1998 and 1999-2001
Jpn. J. Clin. Oncol., March 1, 2004; 34(3): 131 - 136.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. I. Scher, M. Eisenberger, A. V. D'Amico, S. Halabi, E. J. Small, M. Morris, M. W. Kattan, M. Roach, P. Kantoff, K. J. Pienta, et al.
Eligibility and Outcomes Reporting Guidelines for Clinical Trials for Patients in the State of a Rising Prostate-Specific Antigen: Recommendations From the Prostate-Specific Antigen Working Group
J. Clin. Oncol., February 1, 2004; 22(3): 537 - 556.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Ogawa, K. Nakamura, T. Sasaki, T. Yamamoto, M. Koizumi, T. Teshima, T. Inoue, and the Japanese Patterns of Care Study Working Subgro
Radical External Beam Radiotherapy for Prostate Cancer in Japan: Preliminary Results of the 1999-2001 Patterns of Care Process Survey
Jpn. J. Clin. Oncol., January 1, 2004; 34(1): 29 - 36.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. E. Hanks, T. F. Pajak, A. Porter, D. Grignon, H. Brereton, V. Venkatesan, E. M. Horwitz, C. Lawton, S. A. Rosenthal, H. M. Sandler, et al.
Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92-02
J. Clin. Oncol., November 1, 2003; 21(21): 3972 - 3978.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. R. Cooperberg, G. D. Grossfeld, D. P. Lubeck, and P. R. Carroll
National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
J Natl Cancer Inst, July 2, 2003; 95(13): 981 - 989.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. A. Khan and A. W. Partin
Management of High-Risk Populations with Locally Advanced Prostate Cancer
Oncologist, June 1, 2003; 8(3): 259 - 269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Roach III, M. DeSilvio, C. Lawton, V. Uhl, M. Machtay, M.J. Seider, M. Rotman, C. Jones, S.O. Asbell, R.K. Valicenti, et al.
Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413
J. Clin. Oncol., May 15, 2003; 21(10): 1904 - 1911.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
A. Takahashi, M. Yanase, N. Masumori, H. Sasamura, T. Oda, T. Tanaka, N. Itoh, T. Tsukamoto, A. Oouchi, M. Hareyama, et al.
External Beam Radiation Monotherapy for Localized or Locally Advanced Prostate Cancer
Jpn. J. Clin. Oncol., February 1, 2003; 33(2): 73 - 77.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
J. WAXMAN and D. MAZHAR
How are we looking after prostate cancer?
QJM, January 1, 2003; 96(1): 75 - 79.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. Harris and K. N. Lohr
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force
Ann Intern Med, December 3, 2002; 137(11): 917 - 929.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. A. Talcott
Androgen Deprivation as Primary Treatment for Early Prostate Cancer: Should We "Just Do Something"?
J Natl Cancer Inst, March 20, 2002; 94(6): 407 - 409.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Chen, T. DeWeese, J. Dilley, Y. Zhang, Y. Li, N. Ramesh, J. Lee, R. Pennathur-Das, J. Radzyminski, J. Wypych, et al.
CV706, a Prostate Cancer-specific Adenovirus Variant, in Combination with Radiotherapy Produces Synergistic Antitumor Efficacy without Increasing Toxicity
Cancer Res., July 1, 2001; 61(14): 5453 - 5460.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. L. Howe, P. A. Wingo, M. J. Thun, L. A. G. Ries, H. M. Rosenberg, E. G. Feigal, and B. K. Edwards
Annual Report to the Nation on the Status of Cancer (1973 Through 1998), Featuring Cancers With Recent Increasing Trends
J Natl Cancer Inst, June 6, 2001; 93(11): 824 - 842.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. J. Haut, J. F. Harryhill, J. Rosenstock, M. J. Warhol, and R. Vitti
Progressing Prostate Carcinoma
Oncologist, April 1, 2001; 6(2): 183 - 196.
[Abstract] [Full Text]

Home page
 JCOHome page
P. G. S. Cornes, M. Shahidi, L. L. Kestin, and A. A. Martinez
Radiation Endocrine Action in Prostate Cancer
J. Clin. Oncol., December 1, 2000; 18(23): 4004 - 4005.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Cowen, N. Salem, F. Ashoori, R. Meyn, M. L. Meistrich, J. A. Roth, and A. Pollack
Prostate Cancer Radiosensitization in Vivo with Adenovirus-mediated p53 Gene Therapy
Clin. Cancer Res., November 1, 2000; 6(11): 4402 - 4408.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. L. Kestin, A. A. Martinez, J. S. Stromberg, G. K. Edmundson, G. S. Gustafson, D. S. Brabbins, P. Y. Chen, and F. A. Vicini
Matched-Pair Analysis of Conformal High-Dose-Rate Brachytherapy Boost Versus External-Beam Radiation Therapy Alone for Locally Advanced Prostate Cancer
J. Clin. Oncol., August 15, 2000; 18(15): 2869 - 2880.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Valicenti, J. Lu, M. Pilepich, S. Asbell, and D. Grignon
Survival Advantage From Higher-Dose Radiation Therapy for Clinically Localized Prostate Cancer Treated on the Radiation Therapy Oncology Group Trials
J. Clin. Oncol., July 14, 2000; 18(14): 2740 - 2746.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Zelefsky, W. K. Kelly, H. I. Scher, H. Lee, T. Smart, E. Metz, L. Schwartz, Z. Fuks, and S. A. Leibel
Results of a Phase II Study Using Estramustine Phosphate and Vinblastine in Combination With High-Dose Three-Dimensional Conformal Radiotherapy for Patients With Locally Advanced Prostate Cancer
J. Clin. Oncol., May 9, 2000; 18(9): 1936 - 1941.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. M. Messing, J. Manola, M. Sarosdy, G. Wilding, E. D. Crawford, and D. Trump
Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer
N. Engl. J. Med., December 9, 1999; 341(24): 1781 - 1788.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Raghavan
Prostate Cancer Management Under Scrutiny: One Man's Meta-Analysis Is Another Man's Poisson
J. Clin. Oncol., November 1, 1999; 17(11): 3371 - 3373.
[Full Text] [PDF]

Home page
 JCOHome page
W. K. Oh and P. W. Kantoff
Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step?
J. Clin. Oncol., November 1, 1999; 17(11): 3664 - 3675.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
C. A. Lawton, D. Grignon, J. H. Newhouse, P. F. Schellhammer, and D. A. Kuban
Oncodiagnosis Panel: 1997 : Prostatic Carcinoma
RadioGraphics, January 1, 1999; 19(1): 185 - 203.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1997 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online